
    
      Pre-menopausal women with estrogen and/or progesterone receptor positive, metastatic or
      recurrent breast cancer were enrolled and treated with goserelin (Zoladex) monthly and began
      anastrozole (Arimidex) daily for 21 days following the first injection of goserelin.
      Participants continued on treatment until disease progression or unacceptable toxicity.
    
  